Low dose of insulin detemir controls glycaemia, insulinemia and prevents diabetes mellitus progression in the dog with pituitary-dependent hyperadrenocorticism

Research in Veterinary Science

Volumn 93, Issue 1, 2012, Pages 114-120

  Miceli, D D ^a   Gallelli, M F ^a   Cabrera Blatter, M F ^a   Martiarena, B ^a   Branas M M ^a   Ortemberg, L R ^a   Gomez N V ^a   Castillo, V A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Diabetes mellitus; Insulin detemir; Insulin resistance; Pituitary dependent hyperadrenocorticism

Indexed keywords

9 CIS ISOTRETINOIN; CHOLESTEROL; CORTICOTROPIN; CREATININE; GLUCOSE; HYDROCORTISONE; INSULIN; INSULIN DETEMIR; ISOTRETINOIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTISOL CREATININE RATIO; CREATININE URINE LEVEL; DIABETES MELLITUS; DISEASE COURSE; DOG; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HYDROCORTISONE URINE LEVEL; HYPERADRENOCORTICISM; INSULIN RESISTANCE; INSULIN TREATMENT; INSULINEMIA; LOW DRUG DOSE; MALE; MORNING DOSAGE; NONHUMAN; PITUITARY DEPENDENT HYPERADRENOCORTICISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENOCORTICAL HYPERFUNCTION; ADRENOCORTICOTROPIC HORMONE; ANIMALS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS; DOG DISEASES; DOGS; FEMALE; INSULIN; INSULIN, LONG-ACTING; TRIGLYCERIDES;

ANIMALIA; CANIS FAMILIARIS;

EID: 84861480256     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2011.07.003     Document Type: Article

References (62)

1. Al-Majed H.T., Jones P.M., Persaud S.J., Sugden D., Huang G.C., Amiel S., Whitehouse B.J. ACTH stimulates insulin secretion from MIN6 cells and primary mouse and human islets of Langerhans. Journal of Endocrinology 2004, 180:155-166.
2. Andrews R., Walker B. Glucocorticoids and insulin resistance. Old hormones, new targets. Clinical Science 1999, 96:513-523.
3. Barahona M.J., Sucunza N., Resmini E., Fernandez-Real J.M., Ricart W., Moreno-Navarrete J.M., Puig T., Farrerons J., Webb S.M. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. Journal of Clinical Endocrinology & Metabolism 2009, 94:3365-3370.
4. Barahona M.J., Resmini E., Sucunza N., Webb S.M. Diagnosis of cure in Cushinǵs syndrome: lessons from long-term follow-up. Frontiers of Hormone Research 2010, 38:152-157.
5. Beale E.G., Antoine B., Forest C. Glyceroneogenesis in adipocytes: another textbook case. Trends Biochemical Sciences 2003, 28(8):402-403.
6. Beale E.G., Hammer R.E., Antoine B., Forest C. Disregulated glyceroneogenesis: PCK1 as a candidate diabetes and obesity gene. Trends in Endocrinology and Metabolism 2004, 15:129-135.
7. Borthery A.L., Malerbi D.A., Franco L.J. The ROC curve in the evaluation of fasting capillary blood glucose as a screening test for diabetes and IGT. Diabetes Care 2002, 17:1269-1272.
8. Boston B.A., Cone R.D. Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line. Endocrinology 1996, 137:2043-2050.
9. Castillo V.A., Giacomini D.P., Páez-Pereda M., Stalla J., Labeur M., Theodoropoulou M., Holsboer F., Grossman A., Stalla G., Arzt E. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 2006, 174:4438-4444.
10. Castillo V.A., Gomez N.V., Lalia J.C., Cabrera Blatter M.F., Garci{dotless}a J.D. Cushing's disease in dogs: Cabergoline treatment. Research in Veterinary Science 2008, 85:26-34.
11. Castillo V.A., Cabrera Blatter M.F., Gómez N.V., Sinatra V., Gallelli M.F., Ghersevich M.C. Diurnal ACTH and plasma cortisol variations in healthy dogs and in those with pituitary-dependent Cushing's syndrome before and after treatment with retinoic acid. Research in Veterinary Science 2008, 86:223-229.
12. Catchpole B., Ristic J.M., Fleeman L.M., Davison L.J. Canine diabetes mellitus: can old dogs teach us new tricks?. Diabetologia 2005, 48:1948-1956.
13. Chapman T.M., Perry C.M. Insulin Detemir. A review of its use in the management of type-1 and 2 Diabetes Mellitus. Drugs 2004, 64:2577-2595.
14. Colao A., Pivonello R., Spiezia S., Faggiano A., Ferone D., Filippella M., Marzullo P., Cerbone G., Siciliani M., Lombardi G. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. Journal of Clinical Endocrinology and Metabolism 1999, 84:2664-2672.
15. Davani B., Portwood N., Bryzgalova G., Reimer M.K., Heiden T., Ostenson C.G., Okret S., Ahren B., Efendic S., Khan A. Aged transgenic mice with increased glucocorticoid sensitivity in pancreatic beta-cells develop diabetes. Diabetes 2004, 53:S51-S59.
16. Delaunay F., Khan A., Cintra A., Davani B., Ling Z.C., Andersson A., Ostenson C.G., Gustafsson J., Efendic S., Okret S. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. Journal of Clinical Investigation 1997, 100:2094-2098.
17. Drapeau V., Therrien F., Richard D., Tremblay A. Is visceral obesity a physiological adaptation to stress?. Panminerva Medica 2003, 45:189-195.
18. Eigenmann J.E., Peterson M.E. Diabetes mellitus associated with other endocrine disorders. Veterinary Clinics of North America: Journal of Small Animal Practice 1984, 14:837-858.
19. Forest C., Tordjman J., Glorian M., Duplus E., Chauvet G., Quette J., Beale E.G., Antoine B. Fatty acid recycling in adipocytes: a role for glyceroneogenesis and phosphoenolpyruvate carboxykinase. Biochemical Society Transactions 2003, 31:1125-1129.
20. Gagliardino J.J., Borelli M.I., Boschero A.C., Rojas E., Atwater I. Modulatory mechanism of ACTH on insulin secretion: effect on cytosolic Ca2+, membrane potential and Ca2+-ATPase activity. Archives of Physiology and Biochemistry 1995, 103:73-78.
21. Galac S., Kooistra H., Teske E., Rijnberk A. Urinary corticoid/creatinine ratios in the differentiation between pituitary-dependent hyperadrenocorticism and hyperadrenocorticism due to adrenocortical tumour in the dog. Veterinary Quarterly 1997, 19:17-20.
22. Gallelli M.F., Cabrera Blatter M.F., Castillo V.A. A comparative study by age and gender of the pituitary adenoma and ACTH and a-MSH secretion in dogs with pituitary-dependent hyperadrenocorticism. Research in Veterinary Science 2010, 88:33-40.
23. Giacomini D., Paez-Pereda M., Theodoropoulou M., Labeur M., Refojo D., Gerez J., Chervin A., Berner S., Losa M., Buchfelder M., Renner U., Stalla G.K., Arzt E. Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 2006, 147:247-256.
24. Giorgino F., Almahfouz A., Goodyear L.J., Smith R.J. Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo. Journal of Clinical Investigation 1993, 91:2020-2030.
25. Glass D.J. Skeletal muscle hypertrophy and atrophy signaling pathways. International Journal of Biochemistry and Cell Biology 2005, 37:1974-1984.
26. Goulley J., Dahl U., Baeza N., Mishina Y., Edlund H. BMP4-BMPR1A Signaling in β Cells Is Required for and Augments Glucose-Stimulated Insulin Secretion. Cell Metabolism 2007, 5:207-219.
27. Gregoire F.M., Smas C.M., Sul H.S. Understanding adipocyte differentiation. Physiological Reviews 1998, 78:783-809.
28. Hess R.S., Saunder H.M., Van Winkle T.J., Ward C.R. Concurrent disorders in dogs with diabetes mellitus: 221 cases (1993-1998). Journal American Veterinary Medical Association 2000, 217:1166-1173.
29. Kalhan S.C., Mahajan S., Burkett E., Reshef L., Hanson R.W. Glyceroneogenesis and the source of glycerol for hepatic triacylglycerol synthesis in humans. Journal of Biological Chemistry 2001, 276:12928-12931.
30. Kang H.J., Song M.R., Lee S.K., Shin E.C., Choi Y.H., Kim S.J., Lee J.W., Lee M.O. Retinoic acid and its receptors repress the expression and transactivation functions of Nur77: a possible mechanism for the inhibition of apoptosis by retinoic acid. Experimental Cell Research 2000, 256:545-554.
31. Katherman D.A., O'Leary T.P., Richardson R.C. Hyperadrenocorticism and diabetes in the dog. Journal of the American Animal Hospital Association 1980, 16:705-717.
32. Kintzer P., Peterson M. Mitotane (o, p'-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism. Journal of Veterinary Internal Medicine 1991, 5:182-190.
33. Lambillotte C., Gilon P., Henquin J.C. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. Journal of Clinical Investigation 1997, 99:414-423.
34. Landsberg L. Insulin resistance and the metabolic síndrome. Diabetologia 2005, 48:1244-1246.
35. Lebovitz H.E. Insulin resistance. Definition and consequences. Experimental and Clinical Endocrinology and Diabetes 2001, 109:S135-S148.
36. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
37. McGarry J.D. Banting lecture 2001 Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51:7-18.
38. Meij B., Voorhout G., Rijnberk A. Progress in transsphenoidal hypophysectomy for treatment of pituitary-dependent hyperadrenocorticism in dogs and cats. Molecular and Cellular Endocrinology 2002, 197:89-96.
39. Nudi M., Ouimette J.F., Drouin J. BMP (Smad)-mediated repression of POMCn transcription by interference with Pitx/Tpit activity. Molecular Endocrinology 2005, 19:1329-1342.
40. Ohsawa N., Kuzuya T., Tanioka T., Kanazawa Y., Ibayashi H., Nakao K. Effect of administration of ACTH on insulin secretion in dogs. Endocrinology 1967, 81:925-927.
41. Ottosson M., Vikman-Adolfsson K., Enerback S., Olivecrona G., Bjorntorp P. The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. Journal of Clinical Endocrinology and Metabolism 1994, 79:820-825.
42. Paez-Pereda M., Kovalovsky D., Hopfner U., Theodoropoulou M., Pagotto U., Uhl E., Losa M., Stalla J., Grubler Y., Missale C., Arzt E., Stalla G.K. Retinoic acid prevents experimental Cushing syndrome. Journal of Clinical Investigation 2001, 108:1123-1131.
43. Peterson M.E., Nesbitt G.H., Schaer M. Diagnosis and management of concurrent diabetes mellitus and hyperadrenocorticism in thirty dogs. Journal of the American Veterinary Medical Association 1981, 178:66-69.
44. Peterson M.E., Altszuler N., Nichols C.E. Reased insulin sensitivity and glucose tolerance in spontaneous canine hyperadrenocorticism. Research in Veterinary Science 1984 Dec, 36:177-182.
45. Pivonello R., De Martino M.C., De Leo M., Tauchmanovà L., Faggiano A., Lombardi G., Colao A. Cushing's syndrome: aftermath of the cure. Arquivos Brasileiros de Endocrinologia & Metabologia 2007, 51:1381-1391.
46. Ranta F., Avram D., Berchtold S., Dufer M., Drews G., Lang F., Ullrich S. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes 2006, 55:1380-1390.
47. Reshef L., Olswang Y., Cassuto H., Blum B., Croniger C.M., Kalhan S.C., Tilghman S.M., Hanson R.W. Glyceroneogenesis and the triglyceride/fatty acid cycle. Journal of Biological Chemistry 2003, 278:30413-33041.
48. Resmini E., Minuto F., Colao A., Ferone D. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetologica 2009, 46:85-95.
49. Ruzzin J., Wagman A.S., Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 2005, 48:2119-2130.
50. Saad M.J., Folli F., Kahn J.A., Kahn C.R. Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. Journal of Clinical Investigation 1993, 92:2065-2072.
51. Sako, T., Mori, A., Lee, P., Oda, H., Saeki, K., Miki, Y., Kurishima, M., Mimura, K., Nozawa, S., Mizutani, H., Makino, Y., Ishioka, K., Arai, T., 2010. Time-action profiles of insulin detemir in normal and diabetic dogs. Research in Veterinary Science doi:10.1016/j.rvsc.2010.07.001.
52. Schacke H., Docke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacology and Therapeutics 2002, 96:23-43.
53. Shaw J.E., Zimmet P.Z., Hodge A.M., de Courten M., Dowse G.K., Chitson P., Tuomilehto J., Alberti K.G. Impaired fasting glucose: how low should it go?. Diabetes Care 2000, 23:30-34.
54. Sieber-Ruckstuhl N., Boretti F., Wenger M., Maser-Gluth C., Reusch C. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane. Domestic Animal Endocrinology 2006, 31:63-75.
55. Slavin B.G., Ong J.M., Kern P.A. Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. Journal of Lipid Research 1994, 35:1535-1541.
56. Van Raalte D.H., Ouwens D.M., Diamant M. El insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?. European Journal of Clinical Investigation 2009 Nov, 39:81-93.
57. Vegiopoulos A., Herzig S. Glucocorticoids, metabolism and metabolic diseases. Molecular and Cellular Endocrinology 2007, 275:43-61.
58. Verkest K.R., Fleeman L.M., Rand J.S., Morton J.M. Basal measures of insulin sensitivity and insulin secretion and simplified glucose tolerance tests in dogs. Domestic Animal Endocrinology 2010, 39:194-204.
59. Vestergaard H., Bratholm P., Christensen N.J. Increments in insulin sensitivity during intensive treatment are closely correlated with decrements in glucocorticoid receptor mRNA in skeletal muscle from patients with Type II diabetes. Clinical Science 2001, 101:533-540.
60. Walker B.R. Cortisol-cause and cure for metabolic syndrome?. Diabetic Medicine 2006, 23:1281-1288.
61. Webb S.M., Mo D.J., Lamberts S.W.J., Melmed S., Cavagnini F., Giraldi F.P., Strasburger C.J., Zimmermann A.G., Woodmansee W.W. Metabolic, Cardiovascular, and Cerebrovascular Outcomes in Growth Hormone-Deficient Subjects with Previous Cushing's Disease or Non-Functioning Pituitary Adenoma. Journal of Clinical Endocrinology and Metabolism 2010, 95:630-638.
62. Weinstein S.P., Wilson C.M., Pritsker A., Cushman S.W. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism 1998, 47:3-6.